The Filing Desk

Aclaris Therapeutics vs Spyre Therapeutics

Aclaris Therapeutics ACRS · Spyre Therapeutics SYRE · Pharmaceuticals

Side by side

Aclaris TherapeuticsSpyre Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$8M$0M
Revenue growth−58.2%—
Revenue growth a year, last 5 years3.7%—
Gross margin73.3%—
Operating margin−975.9%—
Net margin−829.6%—
Free cash flow−$47M—
Free cash flow margin−603.4%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count58.6%—
Last close$3.92$104.00
P/E at the last close——
Insider trades, last 12 months—sold $435.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aclaris TherapeuticsSpyre Therapeutics
Operating margin
Percent of revenue
Aclaris TherapeuticsSpyre Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aclaris TherapeuticsSpyre Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aclaris Therapeutics and Spyre Therapeutics pages.